Sign up Australia
Proactive Investors - Run By Investors For Investors

Genprex inks research pact with the University of Texas to study anti-cancer agent Oncoprex

Study will focus on the biotech’s active anti-cancer agent Oncoprex to be administered with immunotherapies
A researcher in a lab
The clinical stage gene therapy company will pay MD Anderson US$2mln to conduct the pre-clinical study

Genprex Inc (NASDAQ:GNPX), a clinical-stage gene-therapy company, inked a pact Thursday with the University of Texas MD Anderson Cancer Center for a study focusing on its active anti-cancer agent Oncoprex, to be administered with immunotherapies and research into other tumor suppressor genes.

As a part of the sponsored research agreement, Genprex will pay MD Anderson US$2mln to conduct the pre-clinical study.

The study is titled “A novel therapeutic approach for the treatment of cancer using a combination of the multifactorial tumor suppressor gene TUSC2 and immunotherapy.” TUSC2 is the active agent in Genprex’s investigational non-small-cell, lung cancer drug candidate Oncoprex.

WATCH: Genprex making strides to take cancer-fighting drug Oncoprex to FDA approval

As the title suggests, the study is intended to develop a new therapeutic approach for the treatment of cancer using a combination of the tumor suppressor gene TUSC2 and immunotherapy, including the immune checkpoint inhibitors anti-PD1 and/or anti CTLA-4.

The study may identify biomarkers that can predict the response to therapy across different cancers.

"This research program will evaluate the ability of TUSC2 gene therapy to synergistically enhance the effect and clinical utility of anti-PD1 and/or anti-CTLA-4 therapies,” said Genprex CEO Rodney Varner. “Identifying biomarkers that can predict response rates for Oncoprex-immunotherapy combinations may allow us to explore the utility of this treatment regimen in a broader array of cancers.”

Varner noted that while immunotherapies represent an important advance in treating cancer, even in “highly immunogenic tumors,” most patients “do not respond to checkpoint inhibition.”

“Combination therapies targeting multiple anti-cancer pathways represent a promising approach to achieving greater response rates, and may also allow the expanded use of immunotherapies in a larger population of cancer patients who are not currently candidates for these treatments,” said Varner.

Shares in Genprex were down by a penny to US$7.09 Thursday morning.

View full GNPX profile View Profile

Genprex, Inc. Timeline

Related Articles

The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use